Chimeric antigen receptor T-cell immunotherapy: What pathologists need to know?

Abstract

Chimeric antigen receptor T-cell (CAR-T) immunotherapy genetically modifies patients’ own T cells to specifically target cancer antigens on cell surface. CAR-T uses a single chain chimeric antigen receptor and functions in a manner independent of major histocompatibility complex and antigen processing/presentation. CAR-T has shown dramatic improvements in disease free survival in clinical trials on CD19-positive B-cell malignancies, especially B lymphoblastic leukemia/lymphoma. Because of the revolutionary nature of CAR-T, it is expected to become mainstream anti-cancer therapy in the near future. Pathologists have an essential role in CAR-T related patient care and need to be aware of and prepared for the prime time of CAR-T immunotherapy.

Keywords

Chimeric antigen receptor, cancer immunotherapy, B cells, leukemia, lymphoma

How to Cite

Xu, X., (2016) “Chimeric antigen receptor T-cell immunotherapy: What pathologists need to know?”, Hematopathology 1(1), p.16-22.

96

Views

20

Downloads

Share

Authors

Xiangdong Xu (VA San Diego Healthcare System)

Download

Issue

Publication details

Dates

Licence

Creative Commons Attribution-NonCommercial 4.0

Peer Review

This article has been peer reviewed.

File Checksums (MD5)

  • PDF: 6f86a3a310fc06722b1cadd27dd7fd85